-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Hemolytic anemia spinous process (the SCHA) is a rare, availability, non- immune of decompensated cirrhosis, hemolytic anemia
.
Due to the current lack or limited data describing the prognostic impact, liver transplantation results, and clinical hematological characteristics of SCHA
.
Hemolytic anemia spinous process (the SCHA) is a rare, availability, non- immune of decompensated cirrhosis, hemolytic anemia
The study included 69 eligible SCHA patients
.
The study included 69 eligible SCHA patients
In a multivariate logistic model adjusted for age, gender, etiology of liver cirrhosis, active/recent varicose bleeding, and Child-Turcotte-Pugh score, the OR of the blood transfusion-dependent 90-day mortality rate was 9.
In summary, SCHA was associated with a large amount of additional mortality predicted than MELD-Na or Childhood Turbocott-pugh scores, and was consistently resolved in liver transplantation without recurrence
Original source:
Virk, ZM, Patel, AA, Leaf, RK and Al-Samkari, H.
(2021), Predictors of Mortality and Outcomes of Liver Transplant in Spur Cell Hemolytic Anemia.
Virk, ZM, Patel, AA, Leaf, RK and Al-Samkari, H.
Leave a message here